Login

Journal Front Page

News & Events

  • Call for article for January 2025 issue
    • Submissions of Review, Research Article, Short Communication and Case study are being accepted for the current and future issues before 15 December, 2024 of this journal by online process or editor@ajper.com, or ajper.editor@gmail.com. Further information can be found at www.ajper.com.
  • October 2024 Issue published
    • Dear Researcher, It Pleased to inform you that, Asian Journal of Pharmaceutical Education and Research, has successfully launch Volume 13, Issue 4 (October 2024 Issue). You can find the article on http://ajper.com/current_issue.php Article also invited for the Next coming Issue from your side. For More details Visit: www.ajper.com
  • Application For Reviewer
    • We are now going to reconstitute our editorial board members of Reviewer. Please send your resume at ajper.editor@gmail.com and be a part of the editorial board member as Reviewer.
  • AJPER Impact facor
    • It is to pleasure that Ajper SJIF imact facor has increse from 5.019 to 7.014. Also global impact factor incresed from 0.654 to 0.765.
  • ICV
    • AJPER Rank with Index Copernicus Value 61.10 due to high reputation at International Level

Abstract

FORMULATION & EVALUATION OF LINAGLIPTIN LOADED ETHOSOMES FOR TREATMENT OF DIABETES

Meenakshi Khatarkar*, Vinod Kumar Dhote, Rajesh Singh Pawar

Truba Institute of Pharmacy, Bhopal (M.P.)

ABSTRACT

Diabetes mellitus, one of the most prevalent chronic diseases, is an endocrine and metabolic condition characterised by hyperglycemia and a number of consequences. However, there is still no comprehensive treatment plan for managing diabetes mellitus due to inherent drug deficiencies and restrictions on delivery methods. Ethosomes are non-invasive delivery systems, to deep skin layers and/or the systemic circulation. This study attempts to investigate linagliptin entrapped ethosomes for treatment of diabetes. Ethosomes were prepared as per standard methods & evaluated for various parameters. Results showed that the entrapment efficiency for F4 formulation was found to be 79.85±0.41 and vesicle size was found to be 105.65±0.22nm. The zeta potential for F4 was observed to be -38.5. Commutative % drug release was also found to increase with time. Regression analysis data follows Peppa’s plot. The initial burst release was due to the unbound drug being released from the ethosomes. The release profile of formulation F4 was much better than that of the other formulations tested Overall, the in vitro drug release data for optimized ethosomal formulation F4 showed a sustained release profile. This indicates that formulation F4 could be a suitable option for topical delivery of anti-diabetic drugs.

Keywords: Ethsosmes, Diabetes, Linagliptin, Anti-diabetic drugs, vesicular drug delivery system


[Full Text Article]